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Background: The incidence of cutaneous malignant melanoma, which is mostly attributable (86%) to UV radi-
ation exposure, has been steadily increasing over the past four decades in predominantly fair-skinned popu-
lations. Although public health campaigns are increasing sun-protective behaviour in England, their effect on
melanoma incidence is largely unknown. We conducted a retrospective population-based cohort study to
examine whether there have been changes in the epidemiology of melanoma in England during the past four
decades.
Methods: Individual level data for patients diagnosed with melanoma in England during 19812018 were
obtained from the Office for National Statistics/Public Health England. Average annual incidence rates were
calculated by three age categories (034, 3564, 65+ years), gender and anatomical site during the seven
five-year time periods (198185 to 201115) and the recent three-year period (201618). The percentage
change in incidence was calculated as change in the average incidence rate from the first (198185) to the
last time period (201618). The Average Annual Percentage Change (AAPC) was estimated using the slope of
the linear trend line fitted to the incidence rates by year of diagnosis.
Findings: During the 38-year period (19812018), a total of 265,302 cases of melanoma (45.7% males, 54.3%
females) were registered in England. The average annual number of cases increased from 837/year in 198185
to 6963/year in 201618 in males (+732%), and from 1609/year in 198185 to 6952/year in 201618 in females
(+332%). In the young age-group (034 years), the average annual incidence rates initially increased from
198185 to 200105 and then stabilised during the recent period (200618). In the middle age group (3564
years), the rates increased by +332% (AAPC, 10.4%) in males (from 5.6/100,000 in 198185 to 24.2/100,000 in
201618) and +185% (AAPC, 5.7%) in females (from 10.2/100,000 in 198185 to 29.1/100,000 in 201618); and
in the old age-group (65+ years) the rates increased by +842% (AAPC, 25.7%) in males (from 9.6/100,000 in
198185 to 90.4/100,000 in 201618) and +381% (AAPC, 11.2%) in females (from 12.5/100,000 in 198185 to
60.1/100,000 in 201618). The largest increase in incidence in both males and females was observed for mela-
noma of the trunk (+817%, AAPC, 24.8% in males and +613%, AAPC, 18.3% in females), followed by melanoma of
upper limb (+750%, AAPC, 22.9% in males and 518%, AAPC, 15.5% in females).
Interpretation: It appears that the incidence of melanoma among young people in England has stabilised (or
levelled off) in recent decades, whereas it continues to increase substantially in older population. These find-
ings suggest that public health campaigns targeted at children/adolescents/parents may be favourably influ-
encing melanoma incidence. The steeper increase in incidence in males is consistent with their relatively
greater sun exposure and poor sun-protective behaviour. All the available evidence suggests that the enor-
mous increase in the melanoma of the trunk and upper limb, since the 1980s, is most likely due to increasing
trend in intermittent high intensity recreational UV radiation exposure (e.g. sunbathing, holidaying in places
with strong sunlight, indoor tanning).
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Research in context
Evidence before this study
We searched PubMed from database inception to 31 August
2020, for articles published in English, with titles that included
the search terms (“cutaneous malignant melanoma” or “cutane-
ous melanoma” or “malignant melanoma” or “melanoma” or
“skin cancer”), and titles or abstracts that included the search
terms (“incidence” or “incidence rates” or “melanoma inci-
dence” or “incidence of melanoma” or “incidence trends” or
“time trends” or “trends in incidence”). We also accessed Inter-
national Agency for Research on Cancer/World Health Organi-
zation databases (GLOBOCAN 2018 and Cancer Incidence in Five
Continents) and reports/publications from the Office of National
Statistics and Public Health England.
Over the past four decades, the incidence rates of melanoma
have been increasing at a much faster pace than any other can-
cer in the fair-skinned populations in Europe, North America
and Oceania. It is estimated that 86% of all melanomas in the UK
(i.e. 3.5% of all new cancer cases) are attributable to excessive
UV radiation exposure, and the lifetime risk of developing mel-
anoma in the UK population is approximately 1 in 75. Public
health campaigns are increasing sun-protective behaviour, but
their effect on melanoma incidence is largely unknown, and
there is little information on the changing epidemiology of mel-
anoma with regards to age, gender and anatomical site which
has implications for public health policy and prevention efforts.
Added value of this study
To our knowledge, this is the largest population-based study of
melanoma in England  including 265,302 cases of melanoma
diagnosed over the 38-year period, 19812018  and presents
a comprehensive and up-to-date analysis of the latest trends in
incidence and changing epidemiology of the disease by age,
gender and anatomical site. We have shown, for the first time,
that the incidence rate of melanoma among young people in
England has stabilised (or levelled off) in recent decades,
whereas it continues to increase substantially in older popula-
tion  in people aged 3564 years, it has been increasing (on
average) each year by 10.4% in males and 5.7% in females; and
in people aged 65+ years, it has been increasing (on average)
each year by 25.7% in males and 11.2% in females. We have also
quantified the enormous increase in the incidence of melano-
mas of the trunk and upper limb, and the potential benefits of
effective public health policy and prevention efforts.
Implications of all the available evidence
The stabilisation of incidence of melanoma in young people
emphasise the importance of sustained primary prevention
efforts to further improve the UV radiation protection behav-
iours (i.e. avoidance of excessive sunlight and indoor tanning,
appropriate clothing, and application of sunscreens) and sec-
ondary prevention activities (i.e. increased surveillance, early
detection and prompt treatment of pre-malignant/borderline
lesions) to reduce the incidence of, and mortality from, the dis-
ease. All the available evidence suggests that the enormous
increase in the melanomas of the trunk (+817% in males, +613%
in females) and upper limb (+750% in males, +518% in females)
since the 1980s in England can be mostly attributable to
increasing intermittent high intensity recreational UV radiation
exposure due to lifestyle and societal changes (e.g. sunbathing,
holidaying in a place with strong sunlight, indoor tanning, pro-
liferation of the budget holiday industry and airlines, increasing
trend in travel to sunnier locations and use of sunbeds). Consid-
ering that the large majority of melanomas in the UK (86%) and
other high risk populations are potentially preventable, we
have quantified the potential benefits of effective and sustained
primary and secondary prevention efforts to substantially
reduce the burden of the disease  in the population and health
services.
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Over the past four decades, the incidence of cutaneous malignant
melanoma (hereafter, melanoma) has been increasing at a faster pace
than any other cancer in the fair-skinned populations in Europe,
North America and Oceania [1]. Worldwide, melanoma is the 20th
most common cancer  there were an estimated 287,723 new cases
(1.6% of all cancers) and 60,712 deaths (0.6% of all cancer deaths)
from melanoma in the year 2018, and five-year prevalence of
965,623 cases [2]. In Europe, melanoma is the 6th most common can-
cer  there were an estimated 144,209 new cases (3.4% of all can-
cers) and 27,147 deaths (1.4% of all cancer deaths) from melanoma in
2018, and a five-year prevalence of 494,111 cases [2]. The highest
age-standardised incidence rates (standardised to the world standard
population) are observed in Oceania (28.3 per 100,000 population)
and the lowest in Asia and Africa (0.48 and 0.51 per 100,000 popula-
tion, respectively) [2]. In the UK, melanoma is the 5th most common
cancer with about 16,200 new cases (4% of all cancers) and 2300
deaths (1.0% of all cancer deaths) in 2017 [3]. About half of the cases
are diagnosed at ages 65+ years, and the large majority of cases occur
on the trunk in males and on the lower limbs in females [3]. The
cumulative risk of developing melanoma by age 74 is 1.34% (1 in 75)
in males and 1.35% (1 in 74) in females [1].
It is generally believed that melanoma occurs as a result of com-
plex interaction between environmental, genetic and individual host
factors [4]. Important risk factors for melanoma include the number
of common/atypical nevi, skin phenotype, family history of mela-
noma, actinic damage, history of sunburns, and excessive exposure to
ultraviolet (UV) radiation, particularly in childhood and adolescence
[5,6]. Overexposure to UV radiation (or light) from the sun is the
main (and potentially preventable) environmental risk factor for mel-
anoma  it has been estimated that 86% of all melanomas in the UK
(i.e. 3.5% of all new cancer cases) are attributable to UV radiation
exposure [7]. It is generally agreed that this risk is more closely asso-
ciated with intermittent exposure to high-intensity sunlight (e.g.
sunbathing/holidaying in a place with strong sunlight), than to
chronic sunlight exposure (e.g. outdoor work/occupation) [4]. At least
three systematic reviews/meta-analyses have confirmed this hypoth-
esis and provided summary estimates of risk associated with inter-
mittent and chronic sun exposure [810]. There is also emerging
molecular evidence that somatic genetic aberrations in melanoma
not only vary by histology, but also vary by anatomical site suggest-
ing that melanomas arising at different anatomical sites may have
different causal pathways and that the relationship between sun
exposure and melanoma differs by anatomical site and genotype
[11]. It has been suggested that the main reason for the increasing
incidence could be increased exposure, particularly intense, intermit-
tent exposure, of pale white skin to UV radiation [12]. The latent
period from initiation of the carcinogenesis process to clinical presen-
tation is usually more than 10 years [10]. Exposure to artificial sour-
ces of UV radiation from indoor tanning beds/lamps is the second
most important environmental cause of melanoma [13,14]. In a
recent meta-analysis, indoor tanning bed use was associated with a
significant increase in the risk of melanoma and the risk increased
with number of tanning sessions and with initial usage at a young
A. Memon et al. / The Lancet Regional Health - Europe 00 (2021) 100024 3age (<35 years) [13]. In 2009, the WHO’s International Agency for
Research on Cancer (IARC) listed UV radiation and indoor tanning
beds as Class I carcinogens (in the same class as cigarettes, benzene
and asbestos) [14].
While the overall (i.e. all ages combined) incidence rates of mela-
noma in most fair-skinned populations continue to rise, reports from
certain high risk areas such as Australia, New Zealand, USA, western
Europe and Scandinavia show that the incidence, especially in young
adults, has been either stabilising or declining in recent years  sug-
gesting a cohort effect among recent generations, perhaps due to
changes in lifestyle/social behaviour and increasing awareness of
skin cancer and its prevention [12,1517]. In recent years, there have
also been significant changes in the epidemiology of melanoma with
regards to age, gender and anatomical site in most populations 
which have implications for public health policy and prevention
efforts.
We conducted a comprehensive and up-to-date analysis of the
national cancer registration data for England (population, 56.3 Mil-
lion) (www.ons.gov.uk/), for the last four decades (19812018), to
determine the changing epidemiology and trends in age-specific inci-
dence of melanomawith an objective to inform the development of
health education/promotion and primary/secondary prevention ini-
tiatives (e.g. school-based programmes), and public health policy/
interventions (e.g. indoor tanning regulations/laws) for this largely
preventable cancer. It is anticipated that the study will also improve
understanding of the aetiology of melanoma and guide commission-
ing and resource allocation of health/oncology services for patients.
2. Methods
2.1. Data sources
Individual level, national cancer registration data for all patients
diagnosed with cutaneous malignant melanoma (International Clas-
sification of Diseases (ICD) 9th revision codes: 17201729 and ICD-
10 codes: C43.0C43.9) in England, during the 38-year period
19812018, were obtained from the Office for National Statistics
(ONS) and Public Health England (PHE) Office for Data Release 
which is responsible for the collection and collation of registrations
from the nine regional population-based cancer registries in England
(www.ons.gov.uk/) (www.gov.uk/government/publications/access
ing-public-health-england-data/about-the-phe-odr-and-accessing-
data). These regional registries collect information on all cancer
patients in their geographic area directly from primary/secondary
care records, pathology reports and healthcare professionals. Since
the early 1970s, cancer registration in England is of a consistently
high standard with over 98% completion rates [18]. Items of data
obtained included: patient ID number, gender, year of birth, age at
diagnosis, calendar year of diagnosis, topography (ICD 9 and 10
codes) and morphology codes (International Classification of Diseases
for Oncology, 3rd Edition, ICD-O-3). For the calculation of incidence
rates, corresponding annual mid-year national population estimates
by age, gender and calendar year (i.e. the denominator data) were
obtained from the Population Estimates Unit, ONS. Age-standardised
(European standard population) mortality rates of melanoma were
obtained from Cancer Research UK [3] and ONS (www.ons.gov.uk/
peoplepopulationandcommunity/birthsdeathsandmarriages/deaths).
2.2. Statistical analysis
Frequency distribution (N and %) and average annual incidence
rates (per 100,000 population) were calculated according to three
age categories (young age: 034 years, middle age: 3564 years, and
old age: 65+ years), gender and anatomical site during the seven five-
year time periods (198185 to 201115) and the recent three-year
period, 201618, for which the data were available. For comparisonwith other European populations, age-standardised incidence rates
were calculated using the European Standard Population [3]. The per-
centage change in incidence (and mortality) rates in each age-group
and gender was calculated as change in the average incidence (or
mortality) rate from the first (198185) to the last time period
(201618). The Average Annual Percentage Change (AAPC) (i.e. year-
on-year increase in incidence (or mortality) during the 38-year study
period in each age-group was estimated using the slope of the linear
trend line fitted to the incidence (or mortality) rates by year of diag-
nosis (or death). The incidence (or mortality) rates, calculated for
each time period, were regressed against the mid-year of the corre-
sponding time period. For anatomical site specific analysis, melano-
mas were categorised as occurring on the head and neck (ICD-9 and
ICD-10 codes: 17201724, C43.0C43.4), trunk (1725, C43.5), upper
limb (1726, C43.6), and lower limb (1727, C43.7). SPSS (IBM SPSS Sta-
tistics, version 26) was used for data management and coding, Micro-
soft Excel (Microsoft Office 2016) was used for the calculation of
average annual and age-standardised incidence (and mortality) rates
and percentage chance in incidence (and mortality) rates, and SAS
(version 9.4) was used for the calculation of AAPC.
3. Results
During the 38-year study period (19812018), a total of 265,302
cases of cutaneous malignant melanoma (45.7% males, 54.3% females)
were registered in England. The average annual number of new cases
increased from 837/year in 198185 to 6963/year in 201618 in
males (an increase of +732%), and from 1609/year in 198185 to
6952/year in 201618 in females (an increase of +332%).
3.1. Trends in incidence by age and gender
Table 1 and Fig. 1 show the trends in the number of cases and
average annual incidence rates (per 100,000 population) of mela-
noma by age group and gender during the period 19812018. In the
young age-group (034 years), the incidence rates initially increased
from 198185 to 200105 (+156%, AAPC, 7.1% in males and +142%,
AAPC, 6.5% in females) and then stabilised during the recent period
(200618). It is also noteworthy that the rates started out much
higher in females in the 1980s, and remained higher in females than
males in the young age group throughout the study period. As for the
middle and old age-groups, there was a steady and substantial
increase in incidence rates during the study period. In the middle age
group (3564 years), the incidence rates increased by +332% (AAPC,
10.4%) in males (from 5.6/100,000 in 198185 to 24.2/100,000 in
201618) and +185% (AAPC, 5.7%) in females (from 10.2/100,000 in
198185 to 29.1/100,000 in 201618); and in the old age-group (65
+ years) the rates increased by +842% (AAPC, 25.7%) in males (from
9.6/100,000 in 198185 to 90.4/100,000 in 201618) and +381%
(AAPC, 11.2%) in females (from 12.5/100,000 in 198185 to 60.1/
100,000 in 201618). Overall (i.e. for all ages combined), the magni-
tude of increase was relatively much higher in males compared to
females  during the study period, the incidence rates increased by
+584% (AAPC, 17.7%) in males (from 3.7/100,000 in 198185 to 25.3/
100,000 in 201618) and +269% (AAPC, 8.0%) in females (from 6.7/
100,000 in 198185 to 24.7/100,000 in 201618), which, as noted
above, was essentially due to steadily increasing incidence in people
aged 35 years. For comparison with other European populations,
Table 2 presents the trends in age-standardised (European standard
population) incidence rates (per 100,000 population) by gender dur-
ing the period 19812018.
3.2. Trends in incidence by anatomical site
Table 3 and Figs. 25 show the trends in the number of cases and
































































































































































































































































































































































































































































































































































































































































































































4 A. Memon et al. / The Lancet Regional Health - Europe 00 (2021) 100024melanoma by age-group, gender and anatomical site (i.e. head and
neck, trunk, upper limb, and lower limb) during the period
19812018. In the young age-group (034 years)  and in analogy
with the finding in Table 1  the incidence rates at all anatomical
sites initially increased from 198185 to 200105 and then stabi-
lised during the recent period (200618). As for the middle and old
age-groups, there was a steady increase in incidence rates at all ana-
tomical sites during the study period.
In the middle age group (3564 years), the largest increase was
observed in the melanomas of the trunk in both genders (+436%,
AAPC, 13.8% in males and +600%, AAPC, 18.3% in females). In the old
age group (65+ years), the largest increase was observed in the mela-
nomas of the trunk (+1614%, AAPC, 48.7% in males and +745%, AAPC,
20.7% in females) and upper limb (+1527%, AAPC, 46.0% in males and
+770%, AAPC, 22.8% in females). Overall (i.e. for all ages combined)
the largest increase in incidence in both males and females was
observed for melanoma of the trunk (+817%, AAPC, 24.8% in males
and +613%, AAPC, 18.3% in females) followed by melanoma of upper
limb (+750%, AAPC, 22.9% in males and 518%, AAPC, 15.5% in females).
In analogy with the findings in Table 1, the magnitude of increase was
relatively much higher in males compared to females, which was
essentially due to steadily increasing incidence in people aged
35 years (Table 3 and Figs. 25). The anatomical site of the tumour
is most likely associated with the pattern of UV radiation exposure
[4]  overall, the melanoma occurred most commonly on the trunk
in males (42.7%) and on the lower limb in females (43.1%) (Table 3).
3.3. Trends in mortality by gender
For most cancers, trends in mortality reflect trends in incidence
and survival (which is the function of the stage at diagnosis and effi-
cacy of treatment). For example, increasing mortality may reflect
increasing incidence and stable survival, and decreasing (or stable)
mortality may reflect increasing incidence and increasing survival
(due to early diagnosis, e.g. by screening, and improved treatment).
Table 4 shows the trends in average annual mortality rates (per
100,000 population) of melanoma by gender during the period
19812018. In males, the mortality rates increased by +117% (AAPC,
3.9%), from 2.3/100,000 in 198185 to 5.0/100,000 in 201618 and
in females the mortality rates increased by +32% (AAPC, 0.9%), from
2.2/100,000 in 198185 to 2.9/100,000 in 201618. Compared with
the enormous increase in the age-standardised incidence rate of mel-
anoma (+529% in males, +247% in females, Table 2), which is the func-
tion of the aetiology of the disease, the mortality data imply that
there has been a substantial improvement in survival/prognosis 
most likely due to the early diagnosis and improving treatment of the
disease over the last four decades.
4. Discussion
This retrospective population-based cohort study included
265,302 cases of cutaneous malignant melanoma diagnosed during
the 38-year period (19812018), and presents the most comprehen-
sive and up-to-date analysis of the latest trends in the incidence and
changing epidemiology of the disease by age, gender and anatomical
site in England (population, 56.3 Million). The study showed that
overall (i.e. all ages combined), there has been a steady and signifi-
cant increase in the incidence of melanoma in both genders during
the last four decades, which was essentially due to the continually
increasing incidence in middle (age 3564 years) and old ages (65+
years). The steepest increase was observed in males (i.e. more than
two-folds as compared to females) and at old ages. On the other
hand, the study also showed that in young people (aged 034 years)
the incidence rates initially increased from 19812005 and then sta-
bilised (or levelled off) during the last two decades (200618). To
our knowledge, this is the first report to determine the stabilisation
Fig. 1. Trends in average annual incidence rates (per 100,000 population) of cutaneous malignant melanoma by agegroup and gender in England, 19812018. (a) Young age:
034 years, (b) Middle age: 3564 years, (c) Old age: 65+ years, (d) All ages combined.
A. Memon et al. / The Lancet Regional Health - Europe 00 (2021) 100024 5(or levelling off) of melanoma incidence among young people in Eng-
land. With regard to the anatomical site, the largest increase in inci-
dence in both males and females was observed for melanoma of the
trunk, followed by melanoma of upper limb.
The strength of this study includes a novel analysis of the national
population-based cancer registration dataset including 265,302 cases
of melanoma, allowing the calculation of accurate incidence rates
and the trends in incidence over four decades. While the cancer regis-
tration system in England is of a consistently high standard with over
98% completion rates, there is a possibility that information on asmall number of cancer cases exclusively diagnosed and treated in
private hospitals may be incomplete [18]. This is unlikely to have a
material impact as 9899% of hospital activity in England is funded
by the National Health Service (NHS) [18]. All NHS healthcare pro-
viders are mandated to submit cancer data to PHE, and this includes
NHS-funded activity in private hospitals. The cancer registration sys-
tem is an opt-out scheme  i.e. PHE can collect data on individuals
without their consent, unless they choose to opt-out. This is also
unlikely to have a material impact, as the rate of opt-out is <1/10,000
people [18]. Anatomical site was not recorded for 4.9% of the cases
Fig. 1 Continued.
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ing of site improved over time and therefore could have some impact
on the trends. As the data on anatomical site were recorded under
the four broad ICD categories (i.e. head and neck, trunk, upper/lower
limb), lack of information on precise sub-sites (e.g. face, ear, anterior/
posterior trunk) and laterality prevented further insights into thepattern and causative impact of UV radiation exposure, as it seems
likely that sun exposure would lead to a greater increase in lesions
on the posterior trunk relative to the chest and abdomen.
Our finding of the overall increasing incidence of melanoma in
England during the last four decades is in agreement with reports of
increasing incidence in many European countries, North America and
Table 2
Trends in age-standardised (European standard population) average annual incidence rates (per 100,000 population) of cutaneous malignant melanoma by
gender in England, 19812018.
198185 198690 199195 199600 200105 200610 201115 201618 Percentage change
in incidence ratesa
AAPCb
Male 4.5 7.0 8.9 11.4 15.6 21.5 25.9 28.3 +529% 16.3%
Female 7.3 9.8 11.3 12.8 16.4 20.3 23.2 25.3 +247% 7.4%
a Percentage change in the age-standardised average annual incidence rates from the first (198185) to the last time period (201618).
b AAPC, Average Annual Percent Change (i.e. year-on-year increase in incidence rates) during the 38-year study period.
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lished during the last ten or so years have reported either stabilisa-
tion or a slight decline in incidence in younger age groups in some of
these high risk populations, suggesting a birth cohort effect in recent
generations [12,1517,21]. Our finding of the stabilisation (or level-
ling off) of melanoma incidence rates in young people in England is
the second such report (after Norway) from Europe [12,22]. The sta-
bilisation or decline in incidence in cohorts (or generations) born
since the 1980s is probably due to the public health efforts to recog-
nise skin cancer as a major public health problem and improve sun-
protective behaviour, and may be associated with changing UV radia-
tion exposure patterns following a growing awareness of skin cancer
and its risk factors (Examples of skin cancer prevention and early diag-
nosis interventions in England (www.ncin.org.uk/view?rid=2999)
(www.sunsmart.org.uk).
For example, multiple public health campaigns in Queensland,
Australia, started in the early 1980s, were successful in increasing
sun-protective behaviour and were associated with a declining inci-
dence of melanoma, since the mid-to late 1990s, in young people
who were exposed to primary prevention and early detection pro-
grammes since birth [23]. It is noteworthy that this recent stabilisa-
tion of incidence in young people also corresponds with the
widespread availability and use of sunscreens (with sun protection
factor  SPF) since the 1980s (www.nytimes.com/2010/06/24/fash
ion/24skinside.html). Considering that the skin of babies and children
is much more sensitive to UV radiation than adult skin and damage
caused by intermittent exposure to sunlight could lead to the devel-
opment of skin cancer later in life, most of the primary prevention
campaigns are targeted at sun protection during younger years and
educating parents to protect their children. In a systematic review of
epidemiological studies, exposure to high levels of sunlight in child-
hood was found to be a strong determinant of melanoma risk [5].
With regard to gender, we observed a much steeper overall
increase in the incidence rates among males in the middle and old
age-groups and all the anatomical sites. Recent studies have sug-
gested that some of this disparity may be explained by relatively
higher sun exposure and lower knowledge/awareness of skin cancer
and compliance with sun protection measures in men [2426]. It is
generally agreed that alongside sun exposure patterns, individual fac-
tors and response to exposure to UV radiation may also be important
[6]. It has also been suggested that this disparity may be due to bio-
logical differences in skin damage and repair mechanism between
males and females  the male skin is probably more prone to the
damage caused by UV radiation, and female skin is relatively better
at repairing the damage caused by UV radiation [24].
There has been a consistent debate that the role of sunlight in
causing melanoma differs according to the anatomical site. It has
been hypothesised that melanomas at different sites are associated
with distinct pattern of sun exposure. In a case-control study from
Australia, melanomas of the head and neck were associated with
chronic patterns of sun exposure (i.e. high levels of total sun exposure
during adulthood; outdoor work/occupation), whereas melanomas of
the trunk were associated with intermittent patterns of exposure (i.e.
lower levels of sun exposure overall, but higher levels of recreational
exposure on the chest and back) [11]. The authors noted that theirfindings were consistent with other studies that reported that out-
door workers had a relative excess of head and neck melanomas. In
our study, the most common site of melanoma was trunk in males
(42.7%) and lower limb in females (43.1%), and the largest increase in
incidence in both genders was observed for melanoma of the trunk
followed by melanoma of upper limb  suggesting differing patterns
of exposure between males and females and changes in exposure
over the last four decades. Considering the findings of Whiteman
et al. 2006 and others [11,27,28], it appears that a large proportion of
the observed increase in melanoma of the trunk and upper limb in
our study can be attributable to the intermittent high intensity recre-
ational exposure, most likely due to lifestyle changes in recent deca-
des (e.g. sunbathing or holidaying in a place with strong sunlight, use
of indoor tanning beds/lamps, travelling to sunnier locations and use
of sunbeds) [2933]. For example, due to the heightened demand in
recent years, many UK-based holiday companies now offer holiday-
makers a chance to book a ‘prime’ sunbed spot (according to the loca-
tion, intensity, and duration of sunlight) in advance [34]. This
situation, often dubbed by the media as ‘Sunbed wars’, has become
more complex in the midst of the COVID-19 pandemic due to the
new social distancing rules at holiday resorts [35]. Our findings are
consistent with these observations  the more chronically exposed
(i.e. due to outdoor work/occupation) anatomical sites, i.e. head and
neck, showed relatively lower increases in incidence compared to the
intermittently exposed sites, i.e. trunk and upper limb, suggesting an
increase in intermittent high intensity recreational exposure during
the past decades.
The rapidly increasing overall incidence (i.e. all ages and both gen-
ders combined) of melanoma over the past four decades in the fair-
skinned populations in Europe, North America and Oceania is largely
attributable to the lifestyle changes in these decades with increasing
trend in intermittent high intensity recreational UV radiation expo-
sure [9,11]. Some of this increase is also believed to be due to
increased surveillance and early detection [36]. On the other hand,
the most plausible explanations for the stabilisation or slight decline
in incidence rates in recent decades in young people, in some of the
high risk countries, are growing awareness of the dangers of exces-
sive sunbathing, improving sun-protective behaviour, use of sun-
screen and primary and secondary prevention (i.e. early detection
and excision of pigmented lesions) programmes. Simulation studies
have shown that interventions aimed at protecting people during
outdoor recreational activities/outdoor occupational work against
the harmful effects of UV radiation exposure could lead to substantial
reduction in melanoma incidence [37].
5. Conclusions and clinical and public health policy implications
In conclusion, this comprehensive and most up-to-date popula-
tion-based cohort study of the age- gender- and anatomical site-spe-
cific trends in the incidence of cutaneous malignant melanoma in
England showed that overall (i.e. all ages combined) there has been a
substantial increase in the incidence of the disease in both genders
during the last four decades  which was essentially due to the
steadily increasing incidence in middle and old ages, with the steep-
est increase in males and older people. The study also demonstrated,
Table 3
Number of cases and trends in average annual incidence rates (per 100,000 population) of cutaneous malignant melanoma by age-group, gender and anatomical site in England, 19812018.





N Rate N Rate N Rate N Rate N Rate N Rate N Rate N Rate
Head and neck
Male (years)
034 59 0.1 95 0.2 127 0.2 143 0.2 196 0.3 216 0.4 298 0.5 158 0.4 1292 +300% 10.5%
3564 303 0.7 465 1.1 549 1.3 702 1.5 986 2.0 1352 2.6 1667 3.2 1067 3.4 7091 +386% 11.7%
65+ 419 3.0 729 4.9 1079 7.0 1474 9.2 1240 13.3 3495 19.3 5212 25.0 3549 25.9 17,197 +763% 24.3%
All ages 781 0.7 1289 1.1 1755 1.5 2319 1.9 2422 2.8 5063 4.0 7177 5.4 4774 5.8 25,580 +729% 22.7%
Female (years)
034 69 0.1 70 0.1 130 0.2 137 0.2 192 0.3 216 0.4 250 0.4 138 0.4 1202 +300% 10.4%
3564 313 0.8 410 1.0 401 0.9 555 1.2 703 1.4 952 1.8 1077 2.0 701 2.2 5112 +175% 5.3%
65+ 663 3.1 994 4.4 1231 5.4 1362 6.0 1877 8.2 2174 9.3 2897 11.4 1815 11.1 13,013 +258% 8.2%
All ages 1045 0.9 1474 1.2 1762 1.4 2054 1.6 2772 2.2 3342 2.5 4224 3.1 2654 3.1 19,327 +244% 7.8%
Trunk
Male (years)
034 203 0.3 287 0.5 326 0.6 407 0.7 490 0.9 573 1.0 558 0.9 362 1.0 3206 +233% 6.7%
3564 908 2.2 1474 3.5 1967 4.6 2500 5.5 3717 7.6 5128 10.0 5895 11.4 3733 11.8 25,322 +436% 13.8%
65+ 287 2.1 550 3.5 823 5.3 1370 8.5 2218 13.1 3949 21.8 6257 30.0 4934 36.0 20,388 +1614% 48.7%
All ages 1398 1.2 2311 2.0 3116 2.7 4277 3.6 6425 5.3 9650 7.6 12,710 9.6 9029 11.0 48,916 +817% 24.8%
Female (years)
034 223 0.4 329 0.6 435 0.8 499 0.9 769 1.4 849 1.5 920 1.6 564 1.6 4588 +300% 9.7%
3564 509 1.2 767 1.8 971 2.2 1338 2.9 2095 4.2 3181 6.1 3863 7.3 2727 8.4 15,451 +600% 18.3%
65+ 232 1.1 326 1.5 360 1.6 462 2.0 680 3.0 1101 4.7 1759 6.9 1528 9.3 6448 +745% 20.7%
All ages 964 0.8 1422 1.2 1766 1.4 2299 1.8 3544 2.8 5131 3.9 6542 4.8 4819 5.7 26,487 +613% 18.3%
Upper limb
Male (years)
034 97 0.2 142 0.2 184 0.3 203 0.4 204 0.4 261 0.5 265 0.4 144 0.4 1500 +100% 3.7%
3564 389 1.0 636 1.5 735 1.7 1035 2.3 1501 3.1 2108 4.1 2535 4.9 1594 5.0 10,533 +400% 12.8%
65+ 157 1.1 280 1.9 445 2.9 680 4.2 1111 6.6 1943 10.7 3170 15.2 2460 17.9 10,246 +1527% 46.0%
All ages 643 0.6 1058 0.9 1364 1.2 1918 1.6 2819 2.3 4312 3.4 5970 4.5 4198 5.1 22,279 +750% 22.9%
Female (years)
034 184 0.3 295 0.5 371 0.6 382 0.7 499 0.9 491 0.9 596 1.0 343 1.0 3161 +233% 6.9%
3564 745 1.8 1017 2.4 1168 2.7 1546 3.4 2219 4.5 3112 6.0 3701 7.0 2520 7.8 16,028 +333% 10.2%
65+ 434 2.0 564 2.5 821 3.6 1042 4.6 1609 7.1 2423 10.4 3633 14.2 2851 17.4 13,377 +770% 22.8%
All ages 1363 1.1 1876 1.5 2360 1.9 2970 2.4 4327 3.4 6026 4.6 7930 5.8 5714 6.8 32,566 +518% 15.5%
Lower limb
Male (years)
034 123 0.2 219 0.4 219 0.4 227 0.4 309 0.5 274 0.5 289 0.5 179 0.5 1839 +150% 3.7%
3564 468 1.1 624 1.5 687 1.6 904 2.0 1215 2.5 1612 3.2 1878 3.6 1215 3.8 8603 +245% 7.6%
65+ 294 2.1 410 2.8 525 3.4 614 3.8 830 4.9 1270 7.0 1833 8.8 1437 10.5 7213 +400% 11.6%
All ages 885 0.8 1253 1.1 1431 1.2 1745 1.5 2354 1.9 3156 2.5 4000 3.0 2831 3.4 17,655 +325% 9.7%
Female (years)
034 570 1.0 742 1.3 790 1.4 803 1.4 955 1.7 952 1.7 931 1.6 572 1.6 6315 +60% 1.7%
3564 2430 5.8 2895 6.9 3020 7.0 3328 7.2 4250 8.6 5202 10.0 5612 10.7 3474 10.8 30,211 +86% 2.7%
65+ 1130 5.2 1673 7.5 2070 9.1 2456 10.8 3001 13.2 3892 16.7 5106 20.0 3636 22.2 22,964 +327% 9.6%
All ages 4130 3.4 5310 4.4 5880 4.8 6587 5.3 8206 6.4 10,046 7.6 11,649 8.5 7682 9.1 59,490 +168% 5.0%
a Total number of cases (n=265,302) diagnosed during the 38-year study period, 19812018. Of the 265,302 cases, data on anatomical site was missing for 13,002 (4.9%) cases.
b Percentage change in the average annual incidence rates from the first (198185) to the last time period (201618).














Fig. 2. Trends in average annual incidence rates (per 100,000 population) of cutaneous malignant melanoma in persons aged 034 years by anatomical site in England, 19812018.
(a) Male (b) Female.
A. Memon et al. / The Lancet Regional Health - Europe 00 (2021) 100024 9for the first time, the stabilisation (or levelling off) of incidence in
young people during the last two decades. This stabilisation of inci-
dence in young people (i.e. in recent birth cohorts) is encouraging,
and emphasise the importance of continued and sustained primary
prevention efforts, particularly targeting children, adolescents and
their parents, to further improve the UV radiation protection behav-
iours (i.e. avoidance of excessive exposure to sunlight, indoor tanning
beds/lamps and sunbeds, appropriate clothing, and application of
sunscreens) and secondary prevention activities (i.e. increased sur-
veillance, early detection and prompt treatment of pre-malignant/borderline lesions) to reduce the incidence of, and mortality from,
the disease. All the available evidence suggests that this enormous
increase in the incidence of melanomas of the trunk (+817% in males,
+613% in females) and upper limb (+750% in males, +518% in females)
observed during the past four decades in England can be mostly
attributable to increasing trend in intermittent high intensity recrea-
tional UV radiation exposure due to lifestyle and societal changes in
these decades (e.g. sunbathing/holidaying in a place with strong sun-
light, use of indoor tanning beds/lamps, proliferation of the budget
holiday industry and airlines, increasing trend in travel to sunnier
Fig. 3. Trends in average annual incidence rates (per 100,000 population) of cutaneous malignant melanoma in persons aged 3564 years by anatomical site in England,
19812018. (a) Male (b) Female.
10 A. Memon et al. / The Lancet Regional Health - Europe 00 (2021) 100024locations and use of sunbeds). Considering that 86% of all melanomas
in the fair-skinned populations are attributable to UV radiation expo-
sure and are potentially preventable (i.e. majority of the 35,902 cases
out of the 41,747 new cases diagnosed in England during 201618),
this study has quantified the potential benefits of effective and sus-
tained primary and secondary prevention efforts to substantially
reduce the burden of the disease (in the population and health serv-
ices)  thereby making melanoma as one of the most preventable
forms of cancer on a global scale.Funding
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Fig. 5. Percentage change in the average annual incidence rates of cutaneous malignant melanoma from 198185 to 201618, by age group, gender and anatomical site in England,
19812018.
Table 4
Trends in age-standardised (European standard population) average annual mortality rates (per 100,000 population) of cutaneous malignant melanoma by
gender in England, 19812018
198185 198690 199195 199600 200105 200610 201115 201618 Percentage change
in mortality ratesa
AAPCb
Male 2.3 2.6 3.3 3.7 4.1 4.7 5.2 5.0 +117% 3.9%
Female 2.2 2.5 2.7 2.9 2.8 3.0 3.0 2.9 +32% 0.9%
a Percentage change in the age-standardised average annual mortality rates from the first (198185) to the last time period (201618).
b AAPC, Average Annual Percent Change (i.e. year-on-year increase in mortality rates) during the 38-year study period.
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